Extended Data Fig. 4: The pharmacokinetics and biodistribution study of SM–AZE/Paclitaxome-2.
a, Distribution of DLS size via intensity of SM–AZE/Paclitaxome-2. b, Monitoring of DLS size, zeta potential for SM–AZE/Paclitaxome-2 at 4 °C for 14 days (n = 3 independent experiments per group). c, Zeta potential of SM–AZE/Paclitaxome-2 at different pH (n = 3 independent experiments per group). d,e, Blood kinetics (d) and tissue distribution (e) at 24 h in orthotopic 4T1-Luc2 tumor mouse model (n = 3 mice per group, tumors ~300 mm3). f, DLS size distribution by intensity of Cy5-DSPE labled SM–AZE/Paclitaxome-2. Animals were intravenously administered once with SM–AZE/Paclitaxome-2 at 70 mg PTX/kg. HPLC was used to determine the drug levels in primary organs and plasma. g, Lago optical ex vivo photographs of various organs at 24 h in orthotopic 4T1-Luc2 tumor mouse model (n = 3 mice per group, tumors: ~300 mm3) after an i.v. injection with DSPE–Cy5-labeled SM–AZE/Paclitaxome-2 at 70 mg PTX/kg. h, Representative images of extravasation and penetration for SM–AZE/Paclitaxome-2 within the tumors from g using CLSM (n = 3 tumous per group). i, Lago optical ex vivo photographs of various organs at 24 h in orthotopic KPC-Luc tumor mice (n = 3 mice per group, tumors: ~400 mg) after an i.v. injection with DSPE–Cy5-labeled SM–AZE/Paclitaxome-2 at 70 mg PTX/kg. j, Representative images of extravasation and penetration for SM–AZE/Paclitaxome-2 within the tumors from i using CLSM (n = 3 tumors per group). DAPI (blue) was utilized to stain cell nuclei. Primary antibody for PECAM1 first and then Alexa FluorTM 488 detection antibody (green) were used to label the vessels of blood. Scale bars, 50 μm. Data are presented as average ± s.d. within b-e.
